Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation

L’Allier, Philippe L.; Ducharme, Anique; Keller, Pierre-Frédéric; Yu, Holly; Guertin, Marie-Claude; Tardif, Jean‐Claude

doi:10.1016/j.jacc.2004.03.056

Cited by 155 publications

(85 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…For humans, the literature provides conflicting studies on the issue, with some of them supporting no effect of RAS inhibition on AF [27][28][29], whereas other clinical studies have associated the use of both ACE and ARB with a reduced incidence of new-onset AF [30,31], as well as a prevention of AF relapse following electrical cardioversion [32][33][34]. Our results advocate in favor of the beneficial hypothesis for the role of RAS inhibition in AF and there are several pathophysiological mechanisms suggested to support it.…”

Section: Angiotensin II Receptor Blockers and Af Vulnerabilitymentioning

confidence: 99%

Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model

Chrysostomakis

Karalis

Simantirakis

et al. 2007

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

Section: Angiotensin II Receptor Blockers and Af Vulnerabilitymentioning

confidence: 99%

Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model

Chrysostomakis

Karalis

Simantirakis

et al. 2007

Cardiovasc Drugs Ther

View full text Add to dashboard Cite

show abstract

“…In a retrospective analysis of medical utilization records of more than 10,000 patients with hypertension on ACE inhibitor or calcium channel blocker therapy for at least 6 months, treatment with an ACE inhibitor resulted in signifi cantly lower incidence of AF at 4 years and longer time to onset of AF (relative risk, 0.88) [34].…”

Section: Secondary Analysis Of Clinical Trialsmentioning

confidence: 99%

Hypertension and atrial fibrillation

Go¹,

Rosendorff

2009

Curr Cardiol Rep

View full text Add to dashboard Cite

Atrial fibrillation (AF) is an emerging public health problem. The most important risk factor for developing chronic AF is uncontrolled hypertension. Uncontrolled hypertension promotes the initiation and perpetuation of AF through atrial remodeling. Experimental evidence has demonstrated the important role of the renin-angiotensin system in atrial remodeling. Retrospective analysis of several large clinical trials and small prospective trials suggests the beneficial role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in preventing the onset and recurrence of AF in different populations. Several large prospective trials with longer follow-up periods are in progress. These trials may provide definitive evidence for the use of these agents in the prevention of AF.

show abstract

“…However, other studies have shown more disappointing results [ 46 , 48 ]. The VALUE data [ 7 ] and a retrospective study using a national integrated medical and pharmacy claims database in the United States [ 49 ] suggest a possible benefi cial effect of RAS blockers beyond CCBs in hypertensive patients. Almost 5500 patients treated for hypertension with an ACEI were compared with an equal number of matched patients treated with a CCB; at about 4 years of follow-up, the incidence of new AF was signifi cantly lower in the ACEI-treated patients (HR 0.85 [0.74-0.97]) [ 49 ].…”

Section: Antihypertensive Treatment With Ccbsmentioning

confidence: 99%

Prevention of atrial fibrillation in hypertension

Aksnes

Flaa²,

Strand³

et al. 2008

Current Science Inc

View full text Add to dashboard Cite

Hypertensive patients have an increased risk of developing atrial fibrillation (AF), which increases cardiovascular morbidity and mortality in this population. Primary prevention is a new strategy in treating AF; previously, it was more common to focus on preventing adverse outcomes and controlling the arrhythmia's rate and rhythm. In this review, we consider the possible preventive effects of antihypertensive treatment on new-onset AF seen in recent trials, especially with blockers of the renin-angiotensin system (RAS). Several secondary analyses of large, randomized trials regarding hypertension and heart failure have shown promising results with benefits beyond the expected blood pressure-lowering effect. A few prospective studies on prevention of AF recurrence with RAS blockade have been published, and more studies are expected to be published in the near future.

show abstract

Angiotensin-converting enzyme inhibition in hypertensive patients is associated with a reduction in the occurrence of atrial fibrillation

Abstract: Angiotensin-converting enzyme inhibition was associated with a reduced incidence of AF for patients with hypertension in a usual care setting. These results need to be confirmed in a large-scale randomized clinical trial.

Cited by 155 publications

References 40 publications

Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model

Angiotensin II Type 1 Receptor Inhibition is Associated with Reduced Tachyarrhythmia-Induced Ventricular Interstitial Fibrosis in a Goat Atrial Fibrillation Model

Hypertension and atrial fibrillation

Prevention of atrial fibrillation in hypertension

Contact Info

Product

Resources

About